相关实验视频

Updated: Jul 2, 2025

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

H因子对补充激活的控制成为阿尔茨海默病治疗的重要和有前途的治疗目标

Iris Hasantari¹, Nabil Nicolas¹, Philippe Alzieu¹

¹INSERM (Institut National de la Santé et de la Recherche Médicale), Biologie des Maladies Cardiovasculaires, U1034, University Bordeaux, F-33600 Pessac, France.

International journal of molecular sciences

|February 24, 2024

概括

补充抑制H因子可能会减缓阿尔茨海默病 (AD) 的进展. 这项研究表明,H因子降低了炎症和粉样β,改善了AD小鼠的认知功能.

科学领域:

神经科学是一个神经科学.
免疫学免疫学免疫学
病理学病理学病理学

背景情况:

补体系统是天生的免疫系统的一部分,可以加剧炎症并损害血脑屏障.
过度补充活性与阿尔茨海默病 (AD) 病理学和预后不佳有关.
高度炎症发生在阿尔茨海默病的临床前,无症状阶段.

研究的目的:

调查通过H因子抑制补充激活是否可以减轻临床前AD炎症.
为了确定H因子的使用是否可以减缓AD神经病理和认知衰退的发病和进展.

主要方法:

在早期和晚期疾病阶段,向APP/PS1AD小鼠用补充剂抑制剂H因子进行了脑内注射.
量化了促炎性标记物 (IL-6,TNF-α,IL-1β,MAC),粉样β水平和突触标记物 (VGLUT1,PSD95) 的数量.
在接受治疗和对照小鼠中评估了认知功能.

主要成果:

服用H因子可以降低大脑中的IL-6,TNF-α,IL-1β,MAC和β粉样蛋白水平.
在H因子治疗后,突触传播标志物VGLUT1和PSD95在海马中增加.
在接受H因子治疗的APP/PS1小鼠中,认知缺陷得到改善.

结论:

用H因子抑制补体激活显示出对阿尔茨海默病的治疗潜力.
H因子可以抵消AD相关的神经炎症和突触功能障碍.
针对补充系统是AD治疗和预防的一个有希望的策略.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.认知功能认知功能互补系统是互补的系统.这就是H因子H因子.治疗希望是一种治疗希望.

更多相关视频

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy

Published on: November 30, 2018

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...